Brief executive-function assessment tool : A new cognitive impairment screening tool for alcohol and other drug services
Accurate screening for cognitive impairment in alcohol and other drug (AOD) services would help to identify individuals who may need supports to obtain the greatest benefit from substance use disorder (SUD) treatment. At present there is no screening measure that has been developed specifically to detect cognitive impairment in a SUD population. This study examines the psychometric properties of the Brief Executive-function Assessment Tool (BEAT), which was specifically designed for this purpose. This study involving 501 individuals with SUD and 145 normal control participants established internal consistency (n = 646; 0.734), interrater (n = 60; 0.994), and test-retest reliability (n = 177; 0.845), and construct (all correlations p ≤ 0.05), and criterion (n = 467; ANCOVA p < 0.001) validity. Test operating characteristics (n = 500; 87% sensitivity, 71% specificity, 21% PPP, and 99% NPP) were also established relative to an independent criterion variable made up of three established performance-based neuropsychological tests. Findings support the reliability and validity of the BEAT as a screening measure of executive function impairment with high sensitivity and a low rate of false negatives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Applied neuropsychology. Adult - 29(2022), 6 vom: 11. Nov., Seite 1511-1521 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berry, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alcohol and drug |
|---|
| Anmerkungen: |
Date Completed 15.09.2022 Date Revised 15.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/23279095.2021.1895791 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323865070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323865070 | ||
| 003 | DE-627 | ||
| 005 | 20231225185108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/23279095.2021.1895791 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1079.xml |
| 035 | |a (DE-627)NLM323865070 | ||
| 035 | |a (NLM)33831338 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berry, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brief executive-function assessment tool |b A new cognitive impairment screening tool for alcohol and other drug services |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2022 | ||
| 500 | |a Date Revised 15.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Accurate screening for cognitive impairment in alcohol and other drug (AOD) services would help to identify individuals who may need supports to obtain the greatest benefit from substance use disorder (SUD) treatment. At present there is no screening measure that has been developed specifically to detect cognitive impairment in a SUD population. This study examines the psychometric properties of the Brief Executive-function Assessment Tool (BEAT), which was specifically designed for this purpose. This study involving 501 individuals with SUD and 145 normal control participants established internal consistency (n = 646; 0.734), interrater (n = 60; 0.994), and test-retest reliability (n = 177; 0.845), and construct (all correlations p ≤ 0.05), and criterion (n = 467; ANCOVA p < 0.001) validity. Test operating characteristics (n = 500; 87% sensitivity, 71% specificity, 21% PPP, and 99% NPP) were also established relative to an independent criterion variable made up of three established performance-based neuropsychological tests. Findings support the reliability and validity of the BEAT as a screening measure of executive function impairment with high sensitivity and a low rate of false negatives | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alcohol and drug | |
| 650 | 4 | |a executive function impairment | |
| 650 | 4 | |a neuropsychology | |
| 650 | 4 | |a reliability | |
| 650 | 4 | |a screening | |
| 650 | 4 | |a substance use disorder | |
| 650 | 4 | |a validity | |
| 700 | 1 | |a Shores, E A |e verfasserin |4 aut | |
| 700 | 1 | |a Nardo, T |e verfasserin |4 aut | |
| 700 | 1 | |a Sedwell, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, J |e verfasserin |4 aut | |
| 700 | 1 | |a Marceau, E M |e verfasserin |4 aut | |
| 700 | 1 | |a Wesseling, A |e verfasserin |4 aut | |
| 700 | 1 | |a Zucco, M |e verfasserin |4 aut | |
| 700 | 1 | |a Sugden-Lingard, S |e verfasserin |4 aut | |
| 700 | 1 | |a Borchard, T |e verfasserin |4 aut | |
| 700 | 1 | |a Batchelor, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied neuropsychology. Adult |d 2012 |g 29(2022), 6 vom: 11. Nov., Seite 1511-1521 |w (DE-627)NLM215898230 |x 2327-9109 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:6 |g day:11 |g month:11 |g pages:1511-1521 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/23279095.2021.1895791 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 6 |b 11 |c 11 |h 1511-1521 | ||